activ serum alphaamylas cystic fibrosi new method use differenti inhibitor measur pancreat salivari type alphaamylas ec 3211 wa appli serum sampl 46 cystic fibrosi cf patient age rang 4 14 year 50 control age group level pancreat type amylas lower cf patient median 265 iu1 control median 815 p less 0001 result salivarytyp enzym howev support previous report find higher usual level cf patient thi discrep probabl due differ analyt method felt thi procedur valu investig patient cystic fibrosi pancreat disord